Translating Pharmacogenomic Research to Therapeutic Potentials

Pharmacogenomics

Volumn , Issue , 2013, Pages 45-61

  Lam, Y W Francis ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

Personalized medicine, biomarker, genomic technologies

Indexed keywords

EID: 84882864516     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391918-2.00002-0     Document Type: Chapter

References (42)

1. Nelson DR, Conlon M, Baralt C, et al. University of Florida Clinical and Translational Science Institute: transformation and translation in personalized medicine. Clin Transl Sci.
2. Pulley J.M., Denny J.C., Peterson J.F., Bernard G.R., Vnencak-Jones C.L., Ramirez A.H., et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther 2012, 92:87-95.
3. Malhotra A.K., Goldman D., Buchanan R.W., Rooney W., Clifton A., Kosmidis M.H., et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 1998, 3:72-75.
4. Malhotra A.K., Goldman D., Mazzanti C., Clifton A., Breier A., Pickar D. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiatry 1998, 3:328-332.
5. Malhotra A.K., Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996, 153:1092-1094.
6. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998, 19:123-132.
7. Arranz M.J., Munro J., Birkett J., Bolonna A., Mancama D., Sodhi M., et al. Pharmacogenetic prediction of clozapine response. Lancet 2000, 355:1615-1616.
8. Alfaro C.L., Lam Y.W., Simpson J., Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999, 19:155-163.
9. Robertson G.R., Liddle C., Clarke S.J. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008, 83:894-897.
10. Centers for Disease Control and Prevention Genetic testing: ACCE model system for collecting, analyzing and disseminating information on genetic tests Accessed March 26, 2012. http://www.cdc.gov/genomics/gtesting/ACCE/FBR/index.htm.
11. EGAPP Working Group Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007, 9:819-825.
12. Holmes D.R., Dehmer G.J., Kaul S., Leifer D., O'Gara P.T., Stein C.M. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010, 122:537-557.
13. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B., et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124:2574-2609.
14. Kirchheiner J., Bauer S., Meineke I., Rohde W., Prang V., Meisel C., et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002, 12:101-109.
15. Furuta T., Shirai N., Kodaira M., Sugimoto M., Nogaki A., Kuriyama S., et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007, 81:521-528.
16. Reese E.S., Daniel Mullins C., Beitelshees A.L., Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012, 32:323-332.
17. Eckman M.H., Rosand J., Greenberg S.M., Gage B.F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009, 150:73-83.
18. You J.H., Tsui K.K., Wong R.S., Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 2009, 86:540-547.
19. Johnson J.A., Roden D.M., Lesko L.J., Ashley E., Klein T.E., Shuldiner A.R. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012, 91:774-776.
20. Roberts J.D., Wells G.A., Le May M.R., Labinaz M., Glover C., Froeschl M., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711.
21. Jha A.K., DesRoches C.M., Campbell E.G., Donelan K., Rao S.R., Ferris T.G., et al. Use of electronic health records in U.S. hospitals. N Engl J Med 2009, 360:1628-1638.
22. Gage B.F., Eby C., Johnson J.A., Deych E., Rieder M.J., Ridker P.M., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84:326-331.
23. Owen R.P., Altman R.B., Klein T.E. PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum Mutat 2008, 29:456-460.
24. IWPC Pharmacogenetic Dosing Algorithm Accessed April 17, 2012. http://pharmgkb.org/drug/PA451906.
25. WarfarinDosing Accessed April 17, 2012. http://www.warfarindosing.org.
26. Michaud V., Vanier M.C., Brouillette D., Roy D., Verret L., Noel N., et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther 2008, 83:740-748.
27. Wu A.H., Wang P., Smith A., Haller C., Drake K., Linder M., et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008, 9:169-178.
28. Stanek E.J., Sanders C.L., Taber KA., Khalid M., Patel A., Verbrugge RR., et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012, 91(3):450-458.
29. Accreditation Council for Pharmaceutical Education Accreditation standards and guidelines for the professional program in pharmacy leading to the doctor of pharmacy degree Accessed April 17, 2012. http://www.acpe-accredit.org/deans/standards.asp.
30. Crews K.R., Gaedigk A., Dunnenberger H.M., Klein T.E., Shen D.D., Callaghan J.T., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012, 91:321-326.
31. Johnson J.A., Gong L., Whirl-Carrillo M., Gage B.F., Scott S.A., Stein C.M., et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90:625-629.
32. Martin M.A., Klein T.E., Dong B.J., Pirmohamed M., Haas D.W., Kroetz D.L. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012, 91:734-738.
33. Scott S.A., Sangkuhl K., Gardner E.E., Stein C.M., Hulot J.S., Johnson J.A., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011, 90:328-332.
34. Wilke R.A., Ramsey L.B., Johnson S.G., Maxwell W.D., McLeod H.L., Voora D., et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther 2012, 92:112-117.
35. Food and Drug Administration Guidance on pharmacogenetic tests and genetic tests for heritable markers Accessed April 16, 2012. http://www.fda.gov/MedicalDevices/DeviceRegulationsandGuidance/GuidanceD ocuments/ucm077862.htm.
36. Elkin E.B., Weinstein M.C., Winer E.P., Kuntz K.M., Schnitt S.J., Weeks J.C. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004, 22:854-863.
37. Cohen J., Wilson A., Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J 2012, [Epub date is Jan 11, 2012]. 10.1038/tpj.2011.63.
38. Blair E.D. Assessing the value-adding impact of diagnostic-type tests on drug development and marketing. Mol Diagn Ther 2008, 12:331-337.
39. Bevan J.L., Lynch J.A., Dubriwny T.N., Harris T.M., Achter P.J., Reeder A.L., et al. Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med 2003, 5:393-399.
40. Janssens A.C., Gwinn M., Bradley L.A., Oostra B.A., van Duijn C.M., et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008, 82:593-599.
41. Ashley E.A., Butte A.J., Wheeler M.T., Chen R., Klein T.E., Dewey F.E., et al. Clinical assessment incorporating a personal genome. Lancet 2010, 375:1525-1535.
42. Singer J.B., Lewitzky S., Leroy E., Yang F., Zhao X., Klickstein L., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010, 42:711-714.